Summary
The relative vitamin D resistance in patients with chronic renal failure and in those with hypoparathyroidism is due to an impairment of 1-hydroxylation of cholecalciferol. 5,6-trans-25OHCC, which has a similar steric configuration as 1,25(OH)2CC was examined at a daily dose of 18,000 IU for 14 days in both diseases. Intestinal 47calcium absorption as well as serum calcium level could be normalized in most patients with hypoparathyroidism. The improvement was less in patients with chronic renal failure, suggesting an additional depressing influence of uremia on calcium metabolism.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Avioli, L. V.: The therapeutic approach to hypoparathyroidism. Amer. J. Med. 57, 34–42 (1974)
Arnaud, C. D., Tsao, H. S., Littledike, T.: Radioimmunoassay of human parathyroid hormone in serum. J. clin. Invest. 50, 21–34 (1971)
Brickman, A. S., Coburn, J. W., Norman, A. W.: Action of 1,25-dihydroxycholecalciferol, a potent, kidney-produced metabolite of vitamin D3, in uremic man. New Engl. J. Med. 287, 891–895 (1972)
Brickman, A. S., Coburn, J. W., Massry, S. G., Norman, A. W.: 1,25 Dihydroxy-vitamin D3 in normal man and patients with renal failure. Ann. intern. Med. 80, 161–168 (1974)
Brickman, A. S., Jowsey, J., Sherrard, D. J., Friedmann, G., Singer, F. R., Baylink, D. J., Maloney, N., Massry, S. G., Norman, A. W., Coburn, J. W.: Therapy with 1,25-dihydroxy-vitamin D3 in the management of renal osteodystrophy. In: Vitamin D and problems related to uremic bone disease. (A. W. Norman, K. Schaefer, H. G. Grigoleit, D. v. Herrath, and E. Ritz, eds.) pp. 241–247 Berlin-New York: W. de Gruyter 1975
Dent, C. E., Friedmann, M.: A comparison between A.T. 10 and pure dihydrotachysterol in controlling hypoparathyroidism. Lancet 1964II, 164–168
Fraser, D. R., Kodicek, E.: Unique biosynthesis by kidney of a biologically active vitamin D metabolite. Nature (Lond.) 228, 764–766 (1970)
Haussler, M. R.: Vitamin D3: Metabolism, mode of action and assay of circulating hormonal form. In: Vitamin D and problems related to uremic bone disease. (A. W. Norman, K. Schaefer, H. G. Grigoleit, D. v. Herrath, and E. Ritz, eds.), pp. 25–42. Berlin-New York: W. de Gruyter 1975
Haussler, M. R., Baylink, D. J., Hughes, M. R., Brumbaugh, P. F., Wergedal, J. E., Shen, F. H., Nielsen, R. L., Counts, S. J., Bursac, K. M., McCain, T. A.: The assay of 1α, 25-dihydroxyvitamin D3: Physiologic and pathologic modulation of circulating hormone levels. Clin. Endocr. 5, 151s-165s (1976)
Henderson, R. G., Russell, R. G. G., Ledingham, J. G. G., Smith, R., Oliver, D. O., Walton, R. J., Small, D. G., Preston, C., Warner, G. T., Norman, A. W.: Effects of 1,25-dihydroxycholecalciferol on calcium absorption, muscle weakness, and bone disease in chronic renal failure. Lancet 1974I, 379–384
v. Herrath, D., Schaefer, K., Kraft, D., Grigoleit, H.-G., Koeppe, P.: Treatment of uremic bone disease. Action of 5,6-trans-25-cholecalciferol (a vitamin D-analog) in chronic renal failure. Klin. Wschr. 51, 979–981 (1973a)
v. Herrath, D., Kraft, D., Grigoleit, H.-G., Schaefer, K.: Die Behandlung der urämischen Osteopathie. II. Die Wirkung von 5,6-trans-25Hydroxycholecalciferol bei terminaler Niereninsuffizienz. Dtsch. med. Wschr. 97, 1379–1381 (1973b) (English translation: Germ. Med. 3, 93–95, 1973)
Hesch, R.-D., Gerlach, W., Henning, H. V., Emrich, D., Scheler, F., Kattermann, R.: Untersuchungen zur intestinalen 47Ca-Absorption bei Gesunden und Patienten mit chronischer Niereninsuffizienz. Dtsch. med. Wschr. 97, 1735–1742 (1972)
Hill, L. F., Davies, M., Taylor, C. M., Stanbury, S. W.: Treatment of hypoparathyroidism with 1,25-dihydroxycholecalciferol. Clin. Endocr. 5, 167s-173s (1976)
Holick, M. F., Schnoes, H. K., DeLuca, H. F., Suda, T., Cousins, R. J.: Isolation and identification of 1,25-dihydroxycholecalciferol. A metabolite of vitamin D active in intestine. Biochemistry 10, 2799–2804 (1971)
Holick, M. F., Garabedian, M., DeLuca, H. F.: 5,6-trans-25-hydroxycholecalciferol: Vitamin D analog effective on intestine of anephric rats. Science 176, 1247–1248 (1972a)
Holick, M. F., Garabedian, M., DeLuca, H. F.: 5,6-trans isomers of cholecalciferol and 25-hydroxycholecalciferol. Substitutes for 1,25-dihydroxycholecalciferol in anephric animals. Biochemistry 11, 2715–2719 (1972b)
Hunt, G., Morgan, D. B.: The early effects of dihydrotachysterol on calcium and phosphorus metabolism in patients with hypoparathyroidism. Clin. Sci. 38, 713–725 (1970)
Kaye, M., Sagar, S.: Dihydrotachysterol in uremia. Clin. Res. 19, 809 (1971)
Kaye, M., Sagar, S.: Effect of dihydrotachysterol on calcium absorption in uremia. Metabolism 21, 815–824 (1972)
Nordin, B. E. C., Horsman, A., Aaron, J.: Diagnostic procedures. In: Calcium, phosphate and magnesium metabolism. (B. E. C. Nordin, ed.) pp. 469–524. Edinburgh-London-New York: Churchill Livingstone 1976
Norman, A. W., Johnson, R. L., Osborn, T. W., Proscal, D. A., Carey, S. C., Hammond, M. L., Mitra, M. N., Pirio, M. R., Rego, A., Wing, R. M., Okamura, W. H.: The chemistry and conformational and biological analysis of vitamin D3, its metabolites and analogues. Clin. Endocr. 5, 121s-143s (1976)
Olson, E. B. Jr., DeLuca, H. F.: Vitamin D: Metabolism and mechanism of action. Wld. Rev. Nutr. Diet. 17, 164 (1973)
Ponchon, G., DeLuca, H. F.: The role of the liver in the metabolism of vitamin D. J. clin. Invest. 48, 1273–1279 (1969)
Reynolds, J. J., Holick, M. F., DeLuca, H. F.: The effects of vitamin D analogues on bone resorption. Calcif. Tiss. Res. 15, 333–339 (1974)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kraft, D., Offermann, G. The effect of 5,6-trans-25-hydroxycholecalciferol in relative vitamin D resistancy. Naunyn-Schmiedeberg's Arch. Pharmacol. 297, 75–80 (1977). https://doi.org/10.1007/BF00508812
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00508812